source
- FDA grants approval to Revolution Medicines' Rasonque for pancreatic cancerThe U.S. Food and Drug Administration has approved Rasonque, a new therapy from Revolution Medicines, for the treatment of pancreatic cancer. The decision follows data that showed the drug nearly…
- Novartis IL-6 antibody pacibekitug cuts inflammation markers in Phase 2 studyA Phase 2 trial called TRANQUILITY showed that pacibekitug, an IL-6‑targeting antibody acquired by Novartis, reduced several biomarkers of inflammation in participants. The reductions were sustain…